difamilast vs Roflumilast (Zoryve)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: PDE4 · full Atopic Dermatitis pipeline
difamilast · Moizerto / Adquey
Marketed by Aurobindo Pharma and partners
NCT03908970 · Phase 3 · completed
This was a randomized, triple-blind (participant, investigator, and care provider), placebo-controlled Phase 3 trial in 364 adult patients with atopic dermatitis. The primary endpoint was the IGA responder rate at Week 4, which was met: 38.46% (95% CI 31.36–45.95) for 1% OPA-15406 versus 12.64% (95% CI 8.18–18.36) for placebo. The trial was adequately powered and used a validated clinical disease activity measure.
Next expected readout: December 2026 · NCT07173478 (registry estimate)
Reported efficacy
Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): Responder Rate of Investigator's Global Assesment(IGA) of Disease Severity (At Week 4): 1% OPA-15406 38.46% (95% CI 31.36 to 45.95) vs Placebo 12.64% (95% CI 8.18 to 18.36) (met)
Result source: NCT03908970
Roflumilast (Zoryve)
Marketed by Arcutis Biotherapeutics and partners
NCT06631170 · Phase 3 · completed
The trial was randomized, fully blinded, and vehicle-controlled with a validated disease-severity measure as its primary endpoint, and roflumilast cream produced significantly more treatment successes than vehicle (31.9% vs 6.7%, P<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: August 2027 · NCT07560618 (registry estimate)
Reported efficacy
Percentage of subjects with vIGA-AD success (Baseline, week 4): Primary endpoint, Week 4 IGA (vIGA-AD) treatment-success rate: 31.9% with 0.15% roflumilast cream vs 6.7% with vehicle (P<0.0001) (met)
Result source: NCT06631170
Results for Atopic Dermatitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | difamilast | Roflumilast (Zoryve) |
|---|---|---|
| EASI-75 | —Not posted · NCT05571943 | 43.2% vs 22%+21.2 vs placeboNCT047735878 other results
|
| IGA 0/1 with 2-point improvement | —Not posted · NCT05571943 | —Not posted · NCT06631170 |
| EASI-90 | —Not posted · NCT05571943 | 17.4% vs 17.8%−0.4 vs placeboNCT039160815 other results
|
| EASI, % change | —Not posted · NCT05571943 | -69.4% vs -55.8%−13.5 vs placeboNCT039160815 other results
|
EASI-75
- difamilast
- —Not posted · NCT05571943
- Roflumilast (Zoryve)
- 43.2% vs 22%+21.2 vs placeboNCT04773587
8 other results
- 42% vs 19.7% NCT04773600
- 39.4% vs 20.6% NCT04845620
- 56.5% vs 31.1% NCT03916081
- 51.1% vs 31.1% NCT03916081
- 17.4% vs 24.4% NCT03916081
- 31.1% vs 24.4% NCT03916081
- 8.7% vs 2.2% NCT03916081
- 13.3% vs 2.2% NCT03916081
IGA 0/1 with 2-point improvement
- difamilast
- —Not posted · NCT05571943
- Roflumilast (Zoryve)
- —Not posted · NCT06631170
EASI-90
- difamilast
- —Not posted · NCT05571943
- Roflumilast (Zoryve)
- 17.4% vs 17.8%−0.4 vs placeboNCT03916081
5 other results
- 26.7% vs 17.8% NCT03916081
- 2.2% vs 8.9% NCT03916081
- 13.3% vs 8.9% NCT03916081
- 0% vs 0% NCT03916081
- 2.2% vs 0% NCT03916081
EASI, % change
- difamilast
- —Not posted · NCT05571943
- Roflumilast (Zoryve)
- -69.4% vs -55.8%−13.5 vs placeboNCT03916081
5 other results
- -72.3% vs -55.8% NCT03916081
- -54.3% vs -48.5% NCT03916081
- -57.6% vs -48.5% NCT03916081
- -35.8% vs -24.4% NCT03916081
- -34.7% vs -24.4% NCT03916081
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. difamilast: 8 of 8 rows · Roflumilast (Zoryve): 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | difamilast Rows use multiple source trials | Roflumilast (Zoryve) Rows use multiple source trials |
|---|---|---|
| BSA absolute change · percentage points | -3.94% (n=57) vs -0.32% (n=53) placebo @ 4wk0.3%a,b,c NCT02914548 · Phase 2 · registry result, not featured evidence show 1 more dose-3.73% (n=58) vs -0.32% (n=53) placebo @ 4wk1% NCT02914548 · Phase 2 · registry result, not featured evidence | -4.41% (n=46) vs -4.16% (n=45) placebo @ 4wk0.05%a,b,c NCT03916081 · Phase 2 · registry result, not featured evidence show 1 more dose-5.1% (n=45) vs -4.16% (n=45) placebo @ 4wk0.15% NCT03916081 · Phase 2 · registry result, not featured evidence |
| EASI absolute change · score | -4.17 vs -0.08 placebo score @ 4wk1%d,b,c NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 10 other source trials-4.97 vs 0.35 placebo score @ 4wk0.3% NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 -6.07 vs 0.35 placebo score @ 4wk1% NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 -2.21 vs -1.1 placebo score @ 4wk0.3% NCT02068352 · Phase 2 -2 vs -0.51 placebo score @ 4wk0.3% NCT02068352 · Phase 2 -3.19 vs -1.1 placebo score @ 4wk1% NCT02068352 · Phase 2 -3.07 vs -0.51 placebo score @ 4wk1% NCT02068352 · Phase 2 -2.32 vs -0.15 placebo score @ 4wk0.3% NCT02914548 · Phase 2 · registry result, not featured evidence -3.16 vs -0.15 placebo score @ 4wk1% NCT02914548 · Phase 2 · registry result, not featured evidence -5.33 vs 0.56 placebo score @ 4wk0.3% NCT03018691 · Phase 2 · registry result, not featured evidence -5.52 vs 0.56 placebo score @ 4wk1% NCT03018691 · Phase 2 · registry result, not featured evidence | -6.03 vs -4.84 placebo score @ 4wk0.05%a,d,b,c NCT03916081 · Phase 2 · registry result, not featured evidence show 1 more dose-6.44 vs -4.84 placebo score @ 4wk0.15% NCT03916081 · Phase 2 · registry result, not featured evidence |
| IGA 0/1 responder rate · % of participants | 38.46% (n=182) vs 12.64% (n=182) placebo @ 4wk1%e,c NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4 other source trials14.93% (n=67) vs 9.09% (n=66) placebo @ 4wk0.3% NCT02914548 · Phase 2 · registry result, not featured evidence 22.39% (n=67) vs 9.09% (n=66) placebo @ 4wk1% NCT02914548 · Phase 2 · registry result, not featured evidence 37.5% (n=24) vs 8.33% (n=24) placebo @ 4wk0.3% NCT03018691 · Phase 2 · registry result, not featured evidence 40% (n=25) vs 8.33% (n=24) placebo @ 4wk1% NCT03018691 · Phase 2 · registry result, not featured evidence | 41.5% (n=433) vs 25.2% (n=221) placebo @ 4wk0.15% creame,c NCT04773587 · Phase 3 |
| Pruritus VAS absolute change · score | -10.98 vs -7.3 placebo score @ 8wk0.3%a,b,c,f NCT02068352 · Phase 2 show 3 more doses-10.01 vs -7.28 placebo score @ 8wk0.3% NCT02068352 · Phase 2 -20.71 vs -7.3 placebo score @ 8wk1% NCT02068352 · Phase 2 -20.33 vs -7.28 placebo score @ 8wk1% NCT02068352 · Phase 2 | -3.05 vs -1.5 placebo score @ 2.142857wk0.5%b,c,f NCT01856764 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 9.3%1%g NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 19 more results8.4%0.3% NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 10.6%1% NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 24.4%0.3% NCT02068352 · Phase 2 18.6%1% NCT02068352 · Phase 2 8.3%0.3% NCT05372653 · Phase 3 · registry result, not featured evidence 13.8%1% NCT05372653 · Phase 3 · registry result, not featured evidence 25.3%1% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 11.8%0.3% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 8.9%1% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 31.3%0.3% NCT02914548 · Phase 2 · registry result, not featured evidence 20.9%1% NCT02914548 · Phase 2 · registry result, not featured evidence 8.3%0.3% NCT03018691 · Phase 2 · registry result, not featured evidence 4%1% NCT03018691 · Phase 2 · registry result, not featured evidence —0.3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —0.3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —1% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —1% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence | 6.7%0.15% creamh NCT04773587 · Phase 3 show 7 more results9.1%0.15% cream NCT04773600 · Phase 3 6.2%0.05% cream NCT04845620 · Phase 3 34.2%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 33.8%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 8.7%0.05% NCT03916081 · Phase 2 · registry result, not featured evidence 2.2%0.15% NCT03916081 · Phase 2 · registry result, not featured evidence 0%0.5% NCT01856764 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.8%1%g NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 19 more results1.2%0.3% NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 2.4%1% NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 9.8%0.3% NCT02068352 · Phase 2 4.7%1% NCT02068352 · Phase 2 0%0.3% NCT05372653 · Phase 3 · registry result, not featured evidence 3.4%1% NCT05372653 · Phase 3 · registry result, not featured evidence 7.8%1% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 3.5%0.3% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 3.6%1% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 22.4%0.3% NCT02914548 · Phase 2 · registry result, not featured evidence 10.4%1% NCT02914548 · Phase 2 · registry result, not featured evidence 4.2%0.3% NCT03018691 · Phase 2 · registry result, not featured evidence 4%1% NCT03018691 · Phase 2 · registry result, not featured evidence —0.3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —0.3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —1% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —1% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence —3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence | 1.4%0.15% creamh NCT04773587 · Phase 3 show 7 more results1.8%0.15% cream NCT04773600 · Phase 3 1.1%0.05% cream NCT04845620 · Phase 3 2.3%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 4.6%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 2.2%0.05% NCT03916081 · Phase 2 · registry result, not featured evidence 0%0.15% NCT03916081 · Phase 2 · registry result, not featured evidence —0.5% NCT01856764 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%1%g NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 19 more results0%0.3% NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0%1% NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 4.9%0.3% NCT02068352 · Phase 2 4.7%1% NCT02068352 · Phase 2 2.4%0.3% NCT05372653 · Phase 3 · registry result, not featured evidence 3.4%1% NCT05372653 · Phase 3 · registry result, not featured evidence 1.2%1% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 0.7%0.3% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 0%1% ointment NCT03961529 · Phase 3 · registry result, not featured evidence 0%0.3% NCT02914548 · Phase 2 · registry result, not featured evidence 0%1% NCT02914548 · Phase 2 · registry result, not featured evidence 0%0.3% NCT03018691 · Phase 2 · registry result, not featured evidence 0%1% NCT03018691 · Phase 2 · registry result, not featured evidence 0%0.3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence 0%0.3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence 0%1% ointment NCT02334787 · Phase 1 · registry result, not featured evidence 0%1% ointment NCT02334787 · Phase 1 · registry result, not featured evidence 0%3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence 0%3% ointment NCT02334787 · Phase 1 · registry result, not featured evidence | 0.9%0.15% creamh NCT04773587 · Phase 3 show 7 more results0.9%0.15% cream NCT04773600 · Phase 3 0.2%0.05% cream NCT04845620 · Phase 3 1.1%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 1.4%0.15% NCT04804605 · Phase 3 · registry result, not featured evidence 2.2%0.05% NCT03916081 · Phase 2 · registry result, not featured evidence 0%0.15% NCT03916081 · Phase 2 · registry result, not featured evidence 0%0.5% NCT01856764 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 1%g dermatitis atopic 3.8% (placebo 12.1%) NCT03908970 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 show 13 more results0.3% impetigo 7.2% (placebo 6%) nasopharyngitis 6% (placebo 3.6%) NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 1% nasopharyngitis 8.2% (placebo 3.6%) impetigo 2.4% (placebo 6%) NCT03911401 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 0.3% dermatitis atopic 26.8% (placebo 21.6%) nasopharyngitis 7.3% (placebo 8.1%) pruritus 7.3% (placebo 2.7%) NCT02068352 · Phase 2 1% dermatitis atopic 16.3% (placebo 21.6%) headache 7% (placebo 0%) nasopharyngitis 2.3% (placebo 8.1%) NCT02068352 · Phase 2 0.3% nasopharyngitis 43.9% dermatitis contact 19.5% miliaria 12.2% NCT05372653 · Phase 3 · registry result, not featured evidence 1% nasopharyngitis 82.8% gastroenteritis 55.2% dermatitis diaper 34.5% NCT05372653 · Phase 3 · registry result, not featured evidence 1% ointment dermatitis atopic 21.1% nasopharyngitis 14.5% folliculitis 6% NCT03961529 · Phase 3 · registry result, not featured evidence 0.3% ointment nasopharyngitis 32.6% dermatitis atopic 20.8% impetigo 18.1% NCT03961529 · Phase 3 · registry result, not featured evidence 1% ointment dermatitis atopic 30.4% nasopharyngitis 30.4% conjunctivitis allergic 12.5% NCT03961529 · Phase 3 · registry result, not featured evidence 0.3% dermatitis atopic 16.4% (placebo 18.2%) viral upper respiratory tract infection 10.4% (placebo 10.6%) pruritus 7.5% (placebo 6.1%) NCT02914548 · Phase 2 · registry result, not featured evidence 1% dermatitis atopic 9% (placebo 18.2%) viral upper respiratory tract infection 6% (placebo 10.6%) pruritus 1.5% (placebo 6.1%) NCT02914548 · Phase 2 · registry result, not featured evidence 0.3% dermatitis atopic 8.3% (placebo 16.7%) influenza 8.3% (placebo 0%) upper respiratory tract inflammation 4.2% (placebo 8.3%) NCT03018691 · Phase 2 · registry result, not featured evidence 1% upper respiratory tract inflammation 24% (placebo 8.3%) blood alkaline phosphatase increased 8% (placebo 0%) dermatitis atopic 4% (placebo 16.7%) NCT03018691 · Phase 2 · registry result, not featured evidence | 0.15%h covid-19 4.1% nasopharyngitis 2.7% upper respiratory tract infection 2.1% NCT04804605 · Phase 3 · registry result, not featured evidence show 2 more results0.15% covid-19 5.5% upper respiratory tract infection 5.5% nasopharyngitis 3.7% NCT04804605 · Phase 3 · registry result, not featured evidence 0.5% nasopharyngitis 15% (placebo 0%) alanine aminotransferase increased 5% (placebo 0%) application site pain 5% (placebo 5%) NCT01856764 · Phase 2 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dTrial phases differ: Phase 3 versus Phase 2.
- ePopulation context differs: age eligibility differs (adolescents and adults versus includes children).
- fAssessment timepoints differ: 8 weeks versus 2.142857 weeks.
- gPopulation comparability has not been reviewed for 17 of these studies.
- hPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
difamilast
show 6 more results
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 2 more results
show 3 more results
show 3 more results
Roflumilast (Zoryve)
show 17 more results
show 5 more results
show 8 more results
show 19 more results
show 9 more results
show 9 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 2 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: difamilast's landscape · Roflumilast (Zoryve)'s landscape